Short News

Print

short news

 
NMU & PharmEvo plan Workshops
on Medical Writing, Peer Review
on April 1-2, 2019

MULTAN: Nishtar Medical University in collaboration with PharmEvo pharmaceuticals is organizing workshops on Medical Writing and Peer Review on April 1st and 2nd 2019 for its faculty members and postgraduates. Mr.Shaukat Ali Jawaid Chief Editor of Pakistan Journal of Medical Sciences who is also Secretary Easter Mediterranean Association Medical Editors (EMAME) and Dr.Masood Jawaid Associate Editor Pakistan Journal of Medical Sciences who is also Director Medical Affairs at PharmEvo will be the facilitator.

Dr. Ghulam Abbas Assistant Professor of Nephrology and Prof. Nasrin Qaiser Head of the Dept.of Community Medidcine at Nishter Medical University are the local coordinators for this academic activity which will be organized under the auspicious of Dept.of Medial Education at NMU. The programme consists of presentations, interactive discussion and Hands on activity as well. Workshop on Medical Writing will be on April 1st 2019 while Workshop on Medical Editing and Peer Review will be on April 2nd 2019. Dr. Ghulam Abbas from the Dept.of Neurology has been named as the local focal person for these workshops by the Vice Chancellor of NMU. Those interested may contact Dr. Ghulam Abbas.


Cancer moot at SIUT

KARACHI: An international conference being held at SIUT will discuss prevalence and causes of cancer leading to death particularly in developing countries. The conference is jointly organized by prestigious American Society of Clinical Oncology (ASCO) and SIUT. Some leading cancer specialist from Europe and North America are taking part in the conference.


Analysis finds HPV vaccine safe

Infection with human papillomavirus (HPV) can cause certain cancers in women and men, but HPV vaccines are highly effective in preventing infection with oncogenic HPV types. A new British Journal of Clinical Pharmacology review of post-licensure data did not identify any new or unexpected safety concerns of the bivalent HPV vaccine.

The authors analyzed reports submitted to the Vaccine Adverse Event Reporting Systems (VAERS) following bivalent HPV vaccination from 2009-2017. While most HPV vaccine used in the United States during this period was quadrivalent HPV vaccine, 720,000 doses of bivalent HPV vaccine were distributed. VAERS received 241 adverse event reports after bivalent HPV vaccine; 95.8 percent of reports were classified as non-serious. The findings should provide reassurance to patients, parents, and healthcare providers.

Bivalent HPV vaccine is used in more than 134 countries around the world. This review provides additional evidence that bivalent HPV vaccine is safe, and that most adverse reactions are mild and resolve quickly on their own, said lead author Tiffany Suragh, of the Centers for Disease Control and Prevention, in Atlanta.


Cataracts linked to higher risks
of osteoporosis & fracture

A new Journal of the American Geriatrics Society study has evaluated the potential impacts of cataracts and cataract surgery on the risks of osteoporosis and bone fractures.
For the study, researchers at Buddhist Tzu Chi General Hospital in Taiwan studied 57,972 cataract patients who were matched to 57,972 healthy controls. During an average follow-up time of 6.4 years, 17,450 patients developed osteoporosis or fractures in the cataract group, and 12,627 in the non-cataract group. The diagnosis of cataracts was associated with a 29% increased risk of developing osteoporosis or fracture. In analyses for each individual event, the diagnosis of cataracts was associated with a 43% increased risk of osteoporosis, a 16% increased risk of hip fracture, a 25% increased risk of vertebral fracture, and a 24% increased risk of other fractures. In the cataract group, patients who underwent cataract surgery had a 42% lower risk of developing osteoporosis or fracture.


Study explores timing of muscle-
related 
problems of statin use

Statins have been linked with muscle pain and other musculoskeletal adverse events (MAEs) in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.

For the study, cases in which statins (atorvastatin, rosuvastatin, simvastatin, lovastatin, fluvastatin, pitavastatin, and pravastatin) were prescribed were extracted from the US Food and Drug Administration Adverse Event Reporting System Data Files.

The onset timing of statin-induced musculoskeletal adverse events (MAEs) differed with each statin. For example, the onset of MAEs was significantly faster with high-intensity statins including atorvastatin and rosuvastatin than with simvastatin. Concomitant use of drugs-”even those that may increase the risk of MAEs—did not cause changes in the onset timing of MAEs associated with statins.

Passive surveillance of adverse events has played a major role in securing drug safety as a system to detect unknown adverse events. Data mining using Food and Drug Administration Adverse Event Reporting System, which is a large-scale database, will be an aid to enhance drug safety, said senior author Dr. Daiuke Kobayashi, of Josai University, in Japan.

© Professional Medical Publications. All rights reserved.